Document › Details

Oncgnostics GmbH. (4/28/16). "Press Release: Oncgnostics GmbH Cooperates with Sayre Therapeutics in India". Bangalore & Jena.

Region Region India
Organisations Organisation Oncgnostics GmbH
  Organisation 2 Sayre Therapeutics Pvt. Ltd.
Products Product GynTect® test
  Product 2 oncology
Index term Index term Sayre Therapeutics–Oncgnostics: cervical cancer test, 201604– distribution excl of GynTect test in India et al by Sayre Therapeutics Pvt Ltd
Persons Person Hansel, Alfred (Oncgnostics GmbH 201204 Managing Director + Co-founder)
  Person 2 Subramanian, Vandana (Sayre Therapeutics 201604 Head of Business Development)
     


The biotech firm oncgnostics GmbH will start distributing its molecular diagnostic test GynTect for use in cervical cancer diagnostics in an exclusive partnership with Sayre Therapeutics.

GynTect is a molecular test, which allows timely clarification, if a patient with abnormal Pap test finding and/or a positive test for the cancer-causing human papillomaviruses already has or develops a cervical disease that requires treatment. The test provides fast and reliable results and thus quick certainty for the patient. This facilitates the risk assessment for the patient drastically: unnecessarily rash decisions may be avoided, and the chances for a successful treatment are increased. GynTect is already available in the European market, it has received CE IVD mark in the end of 2015. Together with Sayre Therapeutics, oncgnostics intends to address the markets of India, Sri Lanka, Nepal, Bangladesh and Pakistan.

Dr. Alfred Hansel, CEO at oncgnostics, stated “India has the highest prevalence of cervical cancer world-wide with high mortality rates and with the country’s dedicated efforts toward cervical cancer screening , the Indian subcontinent is an attractive market for oncgnostics.”

Vandana Subramanian, Head of Business Development at Sayre stated, ” Cervical cancer, caused by Human Papillomavirus infection, is the leading cancer in Indian women, accounting to nearly 1/4th of the global cervical cancer incidences as well as deaths.

Our collaboration with oncgnostics provides a tremendous boost in our efforts to bring cutting-edge molecular diagnostic products to the Indian subcontinent. Sayre is committed to making available life-saving medicines, devices and diagnostics in South Asia, to benefit the patient community and improve their quality of life.”


Links:

Further information about GynTect® as well as the test procedure, are found here.
Find cost-free picture material concerning this press release, the test and the company here and here.


About Sayre Therapeutics:

M/S Sayre Therapeutics Private Ltd. is South Asia’s only integrated platform for disease management backed by a unique distribution and commercialization model for novel and / or differentiated drugs, companion diagnostics and drug-delivery devices in the super-specialty areas of Oncology and Immunology. Companies with novel Oncology and Immunology assets can work with us in South Asia, as we focus on alleviating life-threatening diseases with high unmet need.

For press releases and other company information, visit: http://www.sayretherapeutics.com or please contact pr@sayretherapeutics.com for further information.

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Oncgnostics GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top